Supplementation of Dual Probiotic Strains Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels

Yonsei University128 enrolled

Overview

The purpose of this study is to evaluate the effect of dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 on triglyceride and apolipoprotein A-V.

A randomized, double-blind, placebo-controlled study was conducted on 128 nondiabetic and hypertriglyceridemic (Plasma Triglyceride, 150-500 mg/dL) subjects. Over a 12 week test period, the probiotic group consumed 2g of powder daily containing dual probiotic strains, while the placebo group consumed the same without probiotics.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

128

Conditions

Hypertriglyceridemia

Interventions

dual probioticsDIETARY_SUPPLEMENT

2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)

placeboDIETARY_SUPPLEMENT

2g of powder daily without probiotics

Eligibility

Sex: ALLMin age: 24 YearsMax age: 68 Years

Medical Language ↔ Plain English

Inclusion Criteria: * nondiabetic (plasma fasting glucose, \<126mg/dL; 2-hour plasma glucose, \<200mg/dL) * borderline to moderate hypertriglyceridemia (plasma triglyceride, 150-500 mg/dL) Exclusion Criteria: * lipid-lowering medications use * any medications or supplement use * any probiotics products use for the past 1 months * dyslipidemia * diabetes mellitus * hypertension * liver disease * renal disease * cardiovascular disease * cerebrovascular disease * pancreatitis * cancer * medication or alcohol abuse * pregnant or breast feeding

Locations (1)

Laboratory of Clinical Nutrigenetics/Nutrigenomics

Seoul, South Korea

Outcomes

Primary Outcomes

ApoA5-1131 genotype

ApoA5-1131 T\>C

Time frame: at baseline

Secondary Outcomes

Fasting glucose at baseline and 12-week follow-up

Serum fasting glucose (mg/dL)

Time frame: 12-week follow-up

Insulin at baseline and 12-week follow-up

Serum insulin (μIU/dL)

Time frame: 12-week follow-up

C-peptide at baseline and 12-week follow-up

Serum C-peptide (μEq/L)

Time frame: 12-week follow-up

Apolipoprotein A-V at baseline and 12-week follow-up

Plasma apolipoprotein A-V (ng/mL)

Time frame: 12-week follow-up

Triglyceride at baseline and 12-week follow-up

Serum triglyceride (mg/dL)

Time frame: 12-week follow-up

Free fatty acid at baseline and 12-week follow-up

Serum free fatty acid (μEq/L)

Time frame: 12-week follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.